Testosterone News and Research

Latest Testosterone News and Research

Endo's FORTESTA Gel for treatment of 'Low T' in males is now available in pharmacies

Endo Pharmaceuticals announced that FORTESTA Gel – recently approved by the U.S. Food and Drug Administration for the treatment of low testosterone, or 'Low T' in adult males – is now available by prescription in pharmacies across the country.

3 Mar 2011

Endo fourth quarter total revenues increase 31% to $511 million

Endo Pharmaceuticals today reported financial results for the fourth quarter 2010.

28 Feb 2011

BioSante completes patient enrollment in LibiGel Phase III trial for treatment of FSD

BioSante Pharmaceuticals, Inc. today announced that enrollment of subjects in the first of two pivotal Phase III LibiGel safety and efficacy trials has been completed.

24 Feb 2011

Skeleton regulates fertility in males, but not females

Researchers at Columbia University Medical Center have discovered that the skeleton acts as a regulator of fertility in male mice through a hormone released by bone, known as osteocalcin.

17 Feb 2011

Molecular explanation to higher tendency for autism among males

George Washington University researcher, Dr. Valerie Hu, Professor of Biochemistry and Molecular Biology, and her team at the School of Medicine and Health Sciences, have found that male and female sex hormones regulate expression of an important gene in neuronal cell culture through a mechanism that could explain not only higher levels of testosterone observed in some individuals with autism, but also why males have a higher incidence of autism than females.

17 Feb 2011

Early balding linked to prostate cancer: Study

Balding early in life causes grief for many men and now new research will cause even more alarm. Researchers have found that early balding may be liked to prostate cancer.

16 Feb 2011

Men going bald at young age more likely to develop prostate cancer in later life

Men who start to lose hair at the age of 20 are more likely to develop prostate cancer in later life and might benefit from screening for the disease, according to a new study published online in the cancer journal, Annals of Oncology today.

15 Feb 2011

State court jury rules in favor of Merck in FOSAMAX trial

Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.

15 Feb 2011

FDA waives NDA filing fee for Antares' Anturol NDA

Antares Pharma, Inc. today announced the receipt from the U.S. Food and Drug Administration (FDA) of a waiver, on February 8, 2011, for the $1,500,000 New Drug Application (NDA) filing fee for Anturol® Gel for overactive bladder (OAB).

14 Feb 2011

Positive safety data from BioSante's ongoing LibiGel Phase III study in women with HSDD

BioSante Pharmaceuticals, today announced positive safety data in its ongoing LibiGel Phase III clinical development program.

13 Feb 2011

New study: Testosterone administration leads to significant reduction in mind reading

A new study from Utrecht and Cambridge Universities has for the first time found that an administration of testosterone under the tongue in volunteers negatively affects a person's ability to 'mind read', an indication of empathy. The findings are published this week in the journal Proceedings of the National Academy of Sciences.

9 Feb 2011

Acupuncture and exercise help women with PCOS

Acupuncture and physical exercise improve hormone levels and menstrual bleeding pattern in women with polycystic ovary syndrome (PCOS), reveals research from the University of Gothenburg, Sweden.

7 Feb 2011

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

7 Feb 2011

Longer life with osteoporosis therapy: Study

In a new breakthrough, Australian scientists have identified the “remarkable” life-extending properties of an osteoporosis treatment. The research is published in the Journal of Endocrinology and Metabolism on Thursday.

3 Feb 2011

Nutritional supplements and seniors: New study

The University of Adelaide will be embarking on a new study that will look into the benefits of providing nutritional supplements and small doses of hormones to elderly people.

2 Feb 2011

Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

Antares Pharma, Inc. today announced that the first patient has been dosed in a clinical study evaluating the VIBEX™ MTX product which is being developed for the treatment of rheumatoid arthritis. The clinical study will evaluate several dose strengths of VIBEX MTX delivered with a proprietary autoinjector versus conventional needle and syringe administration by a healthcare professional.

2 Feb 2011

Lipocine files new patent applications in support of oral testosterone product for hypogonadism

Lipocine Inc. announced today that in addition to its issued patents involving oral testosterone, it has recently filed two new patent applications in support of its oral testosterone product for hypogonadism, also known as low testosterone (low T). These applications cover Lipocine's novel oral testosterone product (LPCN 1021) being developed to overcome the issues with currently marketed topical, parenteral, and transdermal testosterone products.

28 Jan 2011

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for its Melanoma Cancer Vaccine in the treatment of stage IIb to IV melanoma, from the FDA's Office of Orphan Products Development. Melanoma is the most deadly form of skin cancer.

25 Jan 2011

Watson predicts $4.2 billion in revenues from Global Generics and Global Brand businesses

During an investor meeting held today in New York, NY, Watson Pharmaceuticals, Inc. provided an update on its Global businesses, including a detailed overview of its commercial operations and pipeline developments within its Global Generics and Global Brands businesses, and an update of achievements within its Global Operations. In conjunction with the meeting, the Company provided its preliminary 2011 financial and long term growth forecasts.

21 Jan 2011

Women with PCOS face high risk of type 2 diabetes due to aberrations in fat tissue

A study from the University of Gothenburg, shows that women with polycystic ovary syndrome (PCOS) have aberrations in their adipose tissue.

17 Jan 2011

Testosterone News and Research

Latest Testosterone News and Research

Endo's FORTESTA Gel for treatment of 'Low T' in males is now available in pharmacies

Endo fourth quarter total revenues increase 31% to $511 million

BioSante completes patient enrollment in LibiGel Phase III trial for treatment of FSD

Skeleton regulates fertility in males, but not females

Molecular explanation to higher tendency for autism among males

Early balding linked to prostate cancer: Study

Men going bald at young age more likely to develop prostate cancer in later life

State court jury rules in favor of Merck in FOSAMAX trial

FDA waives NDA filing fee for Antares' Anturol NDA

Positive safety data from BioSante's ongoing LibiGel Phase III study in women with HSDD

New study: Testosterone administration leads to significant reduction in mind reading

Acupuncture and exercise help women with PCOS

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Longer life with osteoporosis therapy: Study

Nutritional supplements and seniors: New study

Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

Lipocine files new patent applications in support of oral testosterone product for hypogonadism

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

Watson predicts $4.2 billion in revenues from Global Generics and Global Brand businesses

Women with PCOS face high risk of type 2 diabetes due to aberrations in fat tissue

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Testosterone News and Research

Latest Testosterone News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in